Abbreviated Name

BRL: PNNL

Lead Investigator

Liu, Tao — Pacific Northwest National Laboratory

Coordinating Investigator

No coordinating investigator

Involved Investigators

• Liu, Tao — Pacific Northwest National Laboratory

Abstact

No abstract availalbe.

Aims

Stage I: A feasibility study – comparing a limited number (5) of available scFv library derived antibodies (in a number of antibody formats such as scFv, Fab and IgG) and commercially available monoclonal antibodies directed at the same cancer-associated antigens on the same slide with appropriate controls. This will involve identification, development, and production, of 20 monoclonal antibody pairs specific for 5 antigens with subsequent utilization demonstrated in a micro ELISA assay. The antibody pairs are represented by one detection antibody and 4 capture antibodies derived as affinity matured subclones directed against the same epitope. The capture antibodies will have affinities ranging from 100 nM to 100 pM. Stage II: Extension of the phase I study to ~50 antigens and controls chosen on the basis of potential as cancer biomarkers. In this stage PNNL will: (a) train selected EDRN investigators in the use of the microarray platform, and (b) print a large number of microarrays (1500 slides) for analytical and clinical validation studies.

Analytic Method

No analytic method available.

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

Sep 15 2010

Estimated Finish Date

Sep 14 2015

Protocol ID

231

Protocol Type

Single

Field of Research

Other

Collaborative Group

(No collaborative group)

Cancer Types

• (No cancer types specified)